Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer, 144, 1941–1953.

Article  CAS  PubMed  Google Scholar 

Vogel, A., Martinelli, E., & ESMO Guidelines Committee. (2021). Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice guidelines. Annals of Oncology, 32(6), 801–805.

Article  CAS  PubMed  Google Scholar 

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Xu, D. Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H. Y., Zhu, A. X., & Cheng, A. L. (2020). IMbrave150 investigators. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine, 382(20), 1894–1905.

Article  CAS  PubMed  Google Scholar 

Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 76(3), 681–693.

Article  PubMed  Google Scholar 

Vilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G. P., Sibert, A., Bouattour, M., Lebtahi, R., Allaham, W., Barraud, H., Laurent, V., Mathias, E., Bronowicki, J. P., Tasu, J. P., Perdrisot, R., Silvain, C., Gerolami, R., Mundler, O., Seitz, J. F., Vidal, V., Aubé, C., Oberti, F., Couturier, O., Brenot-Rossi, I., Raoul, J. L., Sarran, A., Costentin, C., Itti, E., Luciani, A., Adam, R., Lewin, M., Samuel, D., Ronot, M., Dinut, A., Castera, L., Chatellier, G., & SARAH Trial Group. (2017). Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. The Lancet Oncology, 18(12), 1624–1636.

Article  CAS  PubMed  Google Scholar 

Chow, P. K. H., Gandhi, M., Tan, S. B., Khin, M. W., Khasbazar, A., Ong, J., Choo, S. P., Cheow, P. C., Chotipanich, C., Lim, K., Lesmana, L. A., Manuaba, T. W., Yoong, B. K., Raj, A., Law, C. S., Cua, I. H. Y., Lobo, R. R., Teh, C. S. C., Kim, Y. H.,   Soo, K. C.; Asia-Pacific Hepatocellular Carcinoma Trials Group. (2018). SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. Journal of Clinical Oncology, 36(19), 1913–1921.

Article  CAS  PubMed  Google Scholar 

Heffernan, N., Cella, D., Webster, K., et al. (2002). Measuring health-related quality of life in patients with hepatobiliary cancers: The functional assessment of cancer therapy-hepatobiliary questionnaire. Journal of Clinical Oncology, 20, 2229–2239.

Article  PubMed  Google Scholar 

Lo, S. H., Sharma, R., Costentin, C. E., Aggio, D., Shergill, S., Colaone, F., Brennan, V. K., Straccia, V. A., Agirrezabal, I., & Lloyd, A. J. (2021). Patient preferences for advanced hepatocellular carcinoma treatment: A multicountry stated preference study. Future Oncology, 17(32), 4275–4287.

Article  CAS  PubMed  Google Scholar 

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J., & SHARP Investigators Study Group. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378–390.

Article  CAS  PubMed  Google Scholar 

Pereira, H., Bouattour, M., Dioguardi Burgio, M., Assenat, E., Grégory, J., Bronowicki, J. P., Chatellier, G., Vilgrain, V., & SARAH Trial Group. (2021). Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). European Journal of Cancer, 154, 46–56.

Article  CAS  PubMed  Google Scholar 

Agirrezabal, I., Brennan, V. K., Colaone, F., Shergill, S., Pereira, H., Chatellier, G., & Vilgrain, V. (2022). Transarterial radioembolization versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison of time to deterioration in quality of life. Advances in Therapy, 39(5), 2035–2051.

Vilgrain, V., Abdel-Rehim, M., Sibert, A., Ronot, M., Lebtahi, R., Castéra, L., & Chatellier, G., & SARAH Trial Group. (2014). Radioembolisation with yttrium–90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): Study protocol for a randomised controlled trial. Trials, 15, 474.

Article  PubMed  PubMed Central  Google Scholar 

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., & de Haes, J. C. (1993). The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.

Article  CAS  PubMed  Google Scholar 

Greenacre, M., Groenen, P. J. F., Hastie, T., Iodice D’Enza, A., Markos, A., & Tuzhilina, E. (2022). Principal component analysis. Nature Reviews Methods Primers, 2(1), 1–21.

Article  Google Scholar 

Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015). Fitting linear mixed-effects models using lme4. Journal of Statistical Software, 67, 1–48.

Article  Google Scholar 

Hagiwara, Y., Shiroiwa, T., Shimozuma, K., Kawahara, T., Uemura, Y., Watanabe, T., Taira, N., Fukuda, T., Ohashi, Y., & Mukai, H. (2018). Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics, 36(2), 215–223.

Article  PubMed  Google Scholar 

Akaike, H. (1998). Information Theory and an Extension of the Maximum Likelihood Principle. In: Parzen E, Tanabe K, Kitagawa G. (Eds.) Selected Papers of Hirotugu Akaike. Springer series in statistics (perspectives in statistics). Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1694-0_15

Schwarz, G. E. (1978). Estimating the dimension of a model. Annals of Statistics, 6(2), 461–464.

Article  Google Scholar 

Fai, A. H., & Cornelius, P. L. (1996). Approximate F-Tests of multiple degree of freedom hypotheses in generalised least squares analyses of unbalanced split-plot experiments. Journal of Statistical Computation and Simulation, 54(4), 363–378.

Article  Google Scholar 

Giesbrecht, F. G., & Burns, J. C. (1985). Two-stage analysis based on a mixed model: Large-sample asymptotic theory and small-sample simulation results. Biometrics, 41(2), 477–486.

Article  Google Scholar 

Mock, V., & Olsen, M. (2003). Current management of fatigue and anemia in patients with cancer. Seminars in Oncology Nursing, 19(4 Suppl 2), 36–41.

Article  PubMed  Google Scholar 

Brose, M. S., Frenette, C. T., Keefe, S. M., & Stein, S. M. (2014). Management of sorafenib-related adverse events: A clinician’s perspective. Seminars in Oncology, 41(Suppl 2), S1–S16.

Article  PubMed  Google Scholar 

Walko, C. M., & Grande, C. (2014). Management of common adverse events in patients treated with sorafenib: Nurse and pharmacist perspective. Seminars in Oncology, 41(Suppl 2), S17–28.

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. (2018). EASL clinical practice guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69, 182–236.

Article  Google Scholar 

Saxena, A., Meteling, B., Kapoor, J., Golani, S., Danta, M., Morris, D. L., & Bester, L. (2014). Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: A single centre experience of 45 consecutive patients. International Journal of Surgery, 12, 1403–1408.

Article  PubMed  Google Scholar 

Weber, M., Lam, M., Chiesa, C., Konijnenberg, M. W., Cremonesi, M., Flamen, P., Gnesin, S., Bodei, L., Kracmerova, T., Luster, M., Garin, E., & Herrmann, K. (2022). EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging, 49, 1682–1699.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Helmberger, T., Golfieri, R., Pech, M., Pfammatter, T., Arnold, D., Cianni, R., Maleux, G., Munneke, G., Pellerin, O., Peynircioglu, B., Sangro, B., Schaefer, N., de Jong, N., & Bilbao, J. I. (2021). Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: First results from the prospective multicentre observational study CIRSE Registry for SIR-Spheres therapy (CIRT). Cardiovascular and Interventional Radiology, 44, 21–25.

Article  PubMed  Google Scholar 

Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., Baron, A., Park, J. W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, T. R. J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., & Cheng, A. L. (2018). Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet, 391(10126), 1163–1173.

Article  CAS  PubMed  Google Scholar 

Pollock, R. F., Colaone, F., Shergill, S., Brennan, V. K., & Agirrezabal, I. (2021). Effects of trial population selection on quality of life and healthcare decision-making: A systematic review and example in the treatment of hepatocellular carcinoma with radioembolization. ClinicoEconomics and Outcomes Research, 13, 835–841.

Article  PubMed  PubMed Central  Google Scholar 

Muszbek, N., Remak, E., Evans, R., Brennan, V. K., Colaone, F., Shergill, S., Mullan, D., & Ross, P. J. (2021). Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Future Oncology, 17, 1055–1068.

Article  CAS  PubMed  Google Scholar 

Agrirrezabal, I., Pereira GrilloJr, L. S., Nasser, F., Brennan, V. K., Bugano, D., Galastri, F. L., de Azeredo-da Silva, A. L. F., Shergill, S., & da Motta-Leal-Filho, J. (2023). Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil. Journal of Medical Economics, 26(1), 731–741.

Article